Scoliosis is a degenerative spinal cord disease that leads to painful and debilitating spinal curvature, and this condition has a high-need for comprehensive diagnostics. Axial Biotech, a biopharmaceutical company, has developed the first scoliosis prognostic test that not only determines how the disease will progress, but does so in a patient-specific manner, enabling personalized medicine and the development of patient tailored treatment plans by doctors. The test is used in patients diagnosed with Scoliosis, and screens for genetic mutations that indicate how the disease will progress in each individual.